A cell culture-derived whole-virus H9N2 vaccine induces high titer antibodies against hemagglutinin and neuraminidase and protects mice from severe lung pathology and weight loss after challenge with a highly virulent H9N2 isolate

Vaccine

Volumn 30, Issue 31, 2012, Pages 4625-4631

  Wodal, Walter ^a   Falkner, Falko G ^a   Kerschbaum, Astrid ^a   Gaiswinkler, Claudia ^a   Fritz, Richard ^a   Kiermayr, Stefan ^a   Portsmouth, Daniel ^a   Savidis Dacho, Helga ^a   Coulibaly, Sogue ^a   Piskernik, Christina ^a   Hohenadl, Christine ^a   Howard, M Keith ^a   Kistner, Otfried ^a   Barrett, P Noel ^a   Kreil, Thomas R ^a  

^a BAXTER BIOSCIENCE   (Austria)

Author keywords

Avian influenza; H9N2; Influenza vaccine; Pandemic influenza; Vero cell culture derived vaccine; Whole virus vaccine

Indexed keywords

CD1 ANTIGEN; INFLUENZA VACCINE; INFLUENZA VIRUS A H9N2 VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; LECTIN; NEUTRALIZING ANTIBODY; SIALIDASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; BIOASSAY; CELL CULTURE; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME ACTIVITY; FEMALE; GUINEA PIG; HEMAGGLUTINATION INHIBITION; HUMAN; IMMUNOHISTOCHEMISTRY; INFLUENZA VIRUS A H9N2; LUNG DISEASE; NONHUMAN; PATHOLOGY; PRIORITY JOURNAL; RAT; VACCINATION; VERO CELL; VIRUS ISOLATION; VIRUS REPLICATION; VIRUS VIRULENCE; WEIGHT REDUCTION; WILD TYPE;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; GUINEA PIGS; HEMAGGLUTINATION INHIBITION TESTS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; INFLUENZA A VIRUS, H9N2 SUBTYPE; INFLUENZA VACCINES; LUNG; MICE; MICE, INBRED BALB C; NEURAMINIDASE; NEUTRALIZATION TESTS; ORTHOMYXOVIRIDAE INFECTIONS; WEIGHT LOSS;

EID: 84861965105     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.04.102     Document Type: Article

References (42)

1. Fusaro A., Monne I., Salviato A., Valastro V., Schivo A., Amarin N.M., et al. Phylogeography and evolutionary history of reassortant H9N2 viruses with potential human health implications. Journal of Virology 2011, 85:8413-8421.
2. Dong G., Luo J., Zhang H., Wang C., Duan M., Deliberto T.J., et al. Phylogenetic diversity and genotypical complexity of H9N2 influenza A viruses revealed by genomic sequence analysis. PLoS One 2011, 6:e17212.
3. Peiris M., Yuen K.Y., Leung C.W., Chan K.H., Ip P.L., Lai R.W., et al. Human infection with influenza H9N2. Lancet 1999, 354:916-917.
4. Butt K.M., Smith G.J., Chen H., Zhang L.J., Leung Y.H., Xu K.M., et al. Human infection with an avian H9N2 influenza A virus in Hong Kong in 2003. Journal of Clinical Microbiology 2005, 43:5760-5767.
5. Lin Y.P., Shaw M., Gregory V., Cameron K., Lim W., Klimov A., et al. Avian-to-human transmission of H9N2 subtype influenza A viruses: relationship between H9N2 and H5N1 human isolates. Proceedings of the National Academy of Sciences of the United States of America 2000, 97:9654-9658.
6. Antigenic and genetic characteristics of influenza A(H5N1) and influenza A(H9N2) viruses for development of candidate vaccines viruses for pandemic preparedness - February 2011. The Weekly Epidemiological Record 2011, 86:93-100.
7. Sun Y., Qin K., Wang J., Pu J., Tang Q., Hu Y., et al. High genetic compatibility and increased pathogenicity of reassortants derived from avian H9N2 and pandemic H1N1/2009 influenza viruses. Proceedings of the National Academy of Sciences of the United States of America 2011, 108:4164-4169.
8. Matrosovich M.N., Krauss S., Webster R.G. H9N2 influenza A viruses from poultry in Asia have human virus-like receptor specificity. Virology 2001, 281:156-162.
9. Wan H., Perez D.R. Amino acid 226 in the hemagglutinin of H9N2 influenza viruses determines cell tropism and replication in human airway epithelial cells. Journal of Virology 2007, 81:5181-5191.
10. Sorrell E.M., Wan H., Araya Y., Song H., Perez D.R. Minimal molecular constraints for respiratory droplet transmission of an avian-human H9N2 influenza A virus. Proceedings of the National Academy of Sciences of the United States of America 2009, 106:7565-7570.
11. Wan H., Sorrell E.M., Song H., Hossain M.J., Ramirez-Nieto G., Monne I., et al. Replication and transmission of H9N2 influenza viruses in ferrets: evaluation of pandemic potential. PLoS One 2008, 3:e2923.
12. Kimble J.B., Sorrell E., Shao H., Martin P.L., Perez D.R. Compatibility of H9N2 avian influenza surface genes and 2009 pandemic H1N1 internal genes for transmission in the ferret model. Proceedings of the National Academy of Sciences of the United States of America 2011, 108:12084-12088.
13. Guan Y., Shortridge K.F., Krauss S., Chin P.S., Dyrting K.C., Ellis T.M., et al. H9N2 influenza viruses possessing H5N1-like internal genomes continue to circulate in poultry in southeastern China. Journal of Virology 2000, 74:9372-9380.
14. Iqbal M., Yaqub T., Reddy K., McCauley J.W. Novel genotypes of H9N2 influenza A viruses isolated from poultry in Pakistan containing NS genes similar to highly pathogenic H7N3 and H5N1 viruses. PLoS One 2009, 4:e5788.
15. Zhang P., Tang Y., Liu X., Liu W., Zhang X., Liu H., et al. A novel genotype H9N2 influenza virus possessing human H5N1 internal genomes has been circulating in poultry in eastern China since 1998. Journal of Virology 2009, 83:8428-8438.
16. Chen H., Subbarao K., Swayne D., Chen Q., Lu X., Katz J., et al. Generation and evaluation of a high-growth reassortant H9N2 influenza A virus as a pandemic vaccine candidate. Vaccine 2003, 21:1974-1979.
17. Hehme N., Engelmann H., Kunzel W., Neumeier E., Sanger R. Pandemic preparedness: lessons learnt from H2N2 and H9N2 candidate vaccines. Medical Microbiology and Immunology 2002, 191:203-208.
18. Lu X., Renshaw M., Tumpey T.M., Kelly G.D., Hu-Primmer J., Katz J.M. Immunity to influenza A H9N2 viruses induced by infection and vaccination. Journal of Virology 2001, 75:4896-4901.
19. Major D.L., Newman R.W., Dunleavy U., Heath A.B., Ploss K., Wood J.M. Evaluation of H9N2 influenza vaccines in BALB/c mice. International Congress Series 2001, 1219:789-794.
20. Nicholson K.G., Thompson C.I., Klap J.M., Wood J.M., Batham S., Newman R.W., et al. Safety and immunogenicity of whole-virus, alum-adjuvanted whole-virus, virosomal, and whole-virus intradermal influenza A/H9N2 vaccine formulations. Vaccine 2009, 28:171-178.
21. Atmar R.L., Keitel W.A., Patel S.M., Katz J.M., She D., El S.H., et al. Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations. Clinical Infectious Diseases 2006, 43:1135-1142.
22. Atmar R.L., Keitel W.A., Quarles J.M., Cate T.R., Patel S.M., Nino D., et al. Evaluation of age-related differences in the immunogenicity of a G9 H9N2 influenza vaccine. Vaccine 2011, 29:8066-8072.
23. Stephenson I., Nicholson K.G., Gluck R., Mischler R., Newman R.W., Palache A.M., et al. Safety and antigenicity of whole virus and subunit influenza A/Hong Kong/1073/99 (H9N2) vaccine in healthy adults: phase I randomised trial. Lancet 2003, 362:1959-1966.
24. Chen H., Matsuoka Y., Swayne D., Chen Q., Cox N.J., Murphy B.R., et al. Generation and characterization of a cold-adapted influenza A H9N2 reassortant as a live pandemic influenza virus vaccine candidate. Vaccine 2003, 21:4430-4436.
25. Karron R.A., Callahan K., Luke C., Thumar B., McAuliffe J., Schappell E., et al. A live attenuated H9N2 influenza vaccine is well tolerated and immunogenic in healthy adults. Journal of Infectious Diseases 2009, 199:711-716.
26. Wu R., Guan Y., Yang Z., Chen J., Wang H., Chen Q., et al. A live bivalent influenza vaccine based on a H9N2 virus strain. Vaccine 2010, 28:673-680.
27. Barrett P.N., Mundt W., Kistner O., Howard M.K. Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines. Expert Review of Vaccines 2009, 8:607-618.
28. Barrett P.N., Portsmouth D., Ehrlich H.J. Developing cell culture-derived pandemic vaccines. Current Opinion in Molecular Therapeutics 2010, 12:21-30.
29. Ehrlich H.J., Muller M., Oh H.M., Tambyah P.A., Joukhadar C., Montomoli E., et al. A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. New England Journal of Medicine 2008, 358:2573-2584.
30. Ehrlich H.J., Muller M., Fritsch S., Zeitlinger M., Berezuk G., Low-Baselli A., et al. A cell culture (Vero)-derived H5N1 whole-virus vaccine induces cross-reactive memory responses. Journal of Infectious Diseases 2009, 200:1113-1118.
31. Howard M.K., Kistner O., Barrett P.N. Pre-clinical development of cell culture (Vero)-derived H5N1 pandemic vaccines. Biological Chemistry 2008, 389:569-577.
32. Kistner O., Howard M.K., Spruth M., Wodal W., Bruhl P., Gerencer M., et al. Cell culture (Vero) derived whole virus (H5N1) vaccine based on wild-type virus strain induces cross-protective immune responses. Vaccine 2007, 25:6028-6036.
33. Kistner O., Crowe B.A., Wodal W., Kerschbaum A., Savidis-Dacho H., Sabarth N., et al. A whole virus pandemic influenza H1N1 vaccine is highly immunogenic and protective in active immunization and passive protection mouse models. PLoS One 2010, 5:e9349.
34. Sabarth N., Howard M.K., Savidis-Dacho H., van Maurik A., Barrett P.N., Kistner O. Comparison of single, homologous prime-boost and heterologous prime-boost immunization strategies against H5N1 influenza virus in a mouse challenge model. Vaccine 2010, 28:650-656.
35. Howard M.K., Sabarth N., Savidis-Dacho H., Portsmouth D., Kistner O., Kreil T.R., et al. H5N1 whole-virus vaccine induces neutralizing antibodies in humans which are protective in a mouse passive transfer model. PLoS One 2011, 6:e23791.
36. Wright P.F. Vaccine preparedness - are we ready for the next influenza pandemic?. New England Journal of Medicine 2008, 358:2540-2543.
37. Wood J.M., Schild G.C., Newman R.W., Seagroatt V. An improved single-radial-immunodiffusion technique for the assay of influenza haemagglutinin antigen: application for potency determinations of inactivated whole virus and subunit vaccines. Journal of Biological Standardization 1977, 5:237-247.
38. Ilyushina N.A., Khalenkov A.M., Seiler J.P., Forrest H.L., Bovin N.V., Marjuki H., et al. Adaptation of pandemic H1N1 influenza viruses in mice. Journal of Virology 2010, 84:8607-8616.
39. Fritz R., Sabarth N., Kiermayr S., Hohenadl C., Howard M.K., Ilk R., et al. A Vero cell-derived whole-virus H5N1 vaccine effectively induces neuraminidase-inhibiting antibodies. Journal of Infectious Diseases 2011, 205:28-34.
40. Mayrhofer J., Coulibaly S., Hessel A., Holzer G.W., Schwendinger M., Bruhl P., et al. Nonreplicating vaccinia virus vectors expressing the H5 influenza virus hemagglutinin produced in modified Vero cells induce robust protection. Journal of Virology 2009, 83:5192-5203.
41. Kundi M. One-hit models for virus inactivation studies. Antiviral Research 1999, 41:145-152.
42. Saito T., Lim W., Suzuki T., Suzuki Y., Kida H., Nishimura S.I., et al. Characterization of a human H9N2 influenza virus isolated in Hong Kong. Vaccine 2001, 20:125-133.